Are COVID-19 vaccines still needed in 2026?
Vaccines continue to aim primarily at reducing severe illness and death. The likely benefit varies by age, immune status and underlying conditions.
Why composition changes
SARS-CoV-2 continues to evolve, so vaccine composition is reviewed regularly. In May 2026 WHO listed monovalent LP.8.1 as the latest recommended antigen, while previously recommended JN.1-lineage antigens remained suitable alternatives.
What vaccines do best
The most consistent benefit is reducing severe disease, hospitalisation and death. Protection against infection and transmission can decrease with time and variant change.
Who benefits most
Older adults, people with chronic conditions or immune suppression, pregnant people and those with higher exposure risk may have greater benefit. Follow the schedule and products available through local health authorities.
Sources
This content is general information, not a diagnosis or individual medical advice. Seek urgent help for severe or rapidly worsening symptoms.